Item not available


Healthcare Associated Infections affect hundreds of thousands of patients unnecessarily each year in the US. These infections are widely regarded as preventable with the implementation of available evidence-based practices across the healthcare continuum of care. Proper evaluation of infection prevention products will assist beside clinicians with complying with the standards and regulations that exist to reduce the incidence of infection.  Supply Chain and Value Analysis professionals play a unique and critical role in reducing infections through proper product analysis, evaluation, and implementation across the entire healthcare delivery system.
Infection Prevention Part 1 will review the critical evidence-based standards specific for infection prevention and control that fall within the three common sources of infection transmission: 1) contaminated hands of the healthcare provider and patient, 2) contaminated environmental surfaces, and 3) contaminated skin of the patient. Finally, the program will provide an overview of a standardized approach to the evaluation of infection prevention and control products, drugs, and medical devices for Supply Chain and Value Analysis professionals.
Each year, Healthcare Associated Infections (HAI’s) cost the US Healthcare system billions of dollars in lost revenue, cause 75,000 deaths, and result in 722,000 unnecessary and preventable infections. These infections directly cause a negative impact of the quality of care, result in increased mortality and morbidity, excess of length of stay, and increased utilization of the healthcare system and supplies to care for these patients. Luckily, these infections are mostly preventable through the implementation of evidence-based practices. The Value Analysis is a critical component of infection prevention and control efforts by sourcing and implementing the most evidence-based practices to reduce the incidence of HAIs, improve the overall experience of care, and reduce costs.
Learning Objectives:
•Discuss the role of the EPA and FDA  in the evaluation of products for Healthcare Associated Infections
•Review the current classification of healthcare disinfectants, skins antiseptics, hand hygiene agents, and medical devices with the FDA and EPA
•Discuss the impact of Healthcare Associated Infections on the IHI Triple Aim
•Review an evidence-based approach to product evaluation for infection prevention and control products
Dr. Hudson Garrett Jr., Vice President, Clinical Affairs PDI Inc